{"id":30553,"date":"2026-10-22T09:14:02","date_gmt":"2026-10-22T15:14:02","guid":{"rendered":"https:\/\/globalhealthintelligence.com\/?p=30553"},"modified":"2026-10-22T09:14:59","modified_gmt":"2026-10-22T15:14:59","slug":"the-traceability-era-preparing-for-brazils-2026-udi-medical-device-mandate","status":"publish","type":"post","link":"https:\/\/globalhealthintelligence.com\/es\/ghi-analysis\/the-traceability-era-preparing-for-brazils-2026-udi-medical-device-mandate\/","title":{"rendered":"The Traceability Era: Preparing for Brazil\u2019s 2026 UDI Medical Device Mandate"},"content":{"rendered":"[vc_row type=\u00bbin_container\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb scene_position=\u00bbcenter\u00bb text_color=\u00bbdark\u00bb text_align=\u00bbleft\u00bb row_border_radius=\u00bbnone\u00bb row_border_radius_applies=\u00bbbg\u00bb overflow=\u00bbvisible\u00bb overlay_strength=\u00bb0.3″ gradient_direction=\u00bbleft_to_right\u00bb shape_divider_position=\u00bbbottom\u00bb bg_image_animation=\u00bbnone\u00bb][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1″ background_hover_color_opacity=\u00bb1″ column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3″ width=\u00bb1\/1″ tablet_width_inherit=\u00bbdefault\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb][vc_column_text css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n

Guillaume Corpart<\/span><\/em><\/p>\n

The sale of medical devices in Latin America\u2019s largest healthcare market is entering a new digital era. Brazil\u2019s Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) has moved its Unique Device Identification (UDI) framework from regulatory planning into operational reality, creating a national database designed to bring greater precision and transparency to the medical device supply chain.<\/p>\n

The centerpiece of this transition is Normative Instruction No. 426\/2026, published in February and effective March 1, 2026. The regulation establishes the requirements for transmitting and managing UDI data within Brazil\u2019s Sistema de Identifica\u00e7\u00e3o \u00danica de Dispositivos M\u00e9dicos (SIUD), the country\u2019s national UDI database. [1][2]\n

This change matters for manufacturers and healthcare providers alike. Brazil\u2019s UDI framework originally required assigning UDI identifiers, placing them on devices, submitting associated information, and using UDI in adverse-event and technical-complaint reporting. [3] Now, with SIUD operational, Brazil has the digital infrastructure to turn those requirements into a functioning national traceability system.<\/p>\n

A New Era of Device Identification<\/h2>\n

UDI is not simply another barcode requirement. It is an internationally recognized system designed to provide an unambiguous identification of medical devices throughout their lifecycle. ANVISA says the objective is to improve post-market surveillance, adverse-event reporting, field actions, and regulatory monitoring while strengthening patient safety. [3]\n

For devices covered by Brazil\u2019s UDI framework, companies must transmit UDI data to SIUD before the device is made available on the Brazilian market once the applicable mandatory deadline arrives. The information transmitted must correspond to the product information approved by ANVISA, with the sanitary authorization holder remaining responsible for ensuring that equivalence. [2]\n

Companies can submit data individually through the SIUD interface or use structured bulk transmission and machine-to-machine communication. They can also authorize third parties to transmit information on their behalf, although the regulatory responsibility remains with the authorization holder. [2] That means UDI compliance increasingly becomes an enterprise-data issue rather than a task confined to regulatory affairs.<\/p>\n

The Compliance Clock Is Already Running<\/h2>\n

One of the most important aspects of the new framework is that the March 2026 effective date does not mean every device must be fully transmitted immediately. According to regulatory guidance, the deadlines are 3.5 years for Class IV devices, four years for Class III, five years for Class II, and six years for Class I. [1][4]\n

That puts the principal mandatory dates at:<\/p>\n